Yüklüyor......
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
PURPOSE: Treatments for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded rapidly. They include the chemotherapies docetaxel and cabazitaxel, hormonal drugs abiraterone and enzalutamide, and best supportive care (BSC). Cabazitaxel has proven to be the last life-prol...
Kaydedildi:
| Yayımlandı: | Pharmacoecon Open |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer International Publishing
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8160066/ https://ncbi.nlm.nih.gov/pubmed/32474839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00219-6 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|